文献速递消化道肿瘤放疗放疗物理与技术

食管及胃食管结合部癌新辅助放化疗中较低与较高放疗剂量的疗效比较:系统综述

Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-05-06

该系统综述纳入110项研究共7577例接受新辅助放化疗的食管及胃食管结合部癌患者,比较较低剂量放疗(BED≤48.85 Gy10)与较高剂量放疗(BED>48.85 Gy10)的疗效与毒性。结果显示较低剂量组无进展生存率和总生存率均显著更高,治疗相关不良事件安全性更好且远处失败率更低。亚组分析提示40.0~41.4 Gy/20~23次常规分割联合现代放疗技术可能提供最佳治疗比。

要点

  • 较低剂量放疗(BED≤48.85 Gy10)患者的总生存率和无进展生存率显著高于较高剂量放疗患者。
  • 较低剂量放疗组治疗相关不良事件安全性更好,远处失败率更低。
  • 40.0~41.4 Gy/20~23次联合现代放疗技术可能为最佳治疗比。

核心结论

  • 基于有限数据,新辅助放化疗采用BED≤48.85 Gy10适合局部晚期可切除的食管及胃食管结合部癌。
  • 采用现代放疗技术给予40.0~41.4 Gy/20~23次可能提供最佳治疗比。

研究设计与样本

  • 系统综述检索Embase和Ovid Medline截至2019年7月的文献,纳入可手术食管及胃食管结合部鳞癌和腺癌接受新辅助放化疗至50.4 Gy/28次的研究。
  • 将物理剂量转换为生物等效剂量(BED,单位Gy,α/β),比较较低剂量放疗(BED≤48.85 Gy10)与较高剂量放疗(BED>48.85 Gy10)的汇总结局。
  • 共纳入110项研究、7577例接受新辅助放化疗的食管及胃食管结合部癌患者进行汇总分析。

主要发现

  • 较低剂量放疗患者的总生存率和无进展生存率均显著高于较高剂量放疗患者。
  • 较低剂量放疗组治疗相关不良事件安全性更好,远处失败率低于较高剂量放疗组。
  • 使用现代放疗技术(包括三维适形放疗和调强放疗)与二维方法相比,肿瘤学结局改善。
  • 亚组分析显示接受40.0~41.4 Gy/20~23次常规分割放疗的患者总生存优于接受高于该剂量者。

关键数值与推荐

  • 较低剂量放疗定义为BED≤48.85 Gy10,较高剂量放疗定义为BED>48.85 Gy10。
  • 亚组分析中常规分割放疗剂量范围为40.0~41.4 Gy,分20~23次。
  • 检索纳入的新辅助放化疗剂量上限为50.4 Gy/28次。

临床怎么用

  • 对于局部晚期可切除的食管及胃食管结合部癌,新辅助放化疗宜选择BED≤48.85 Gy10的较低剂量方案。
  • 可考虑采用40.0~41.4 Gy/20~23次常规分割联合三维适形或调强放疗等现代技术。
  • 避免使用BED>48.85 Gy10的较高剂量,因其与生存获益降低及安全性变差相关。

局限性

  • 结论基于有限数据,为系统综述的汇总分析而非前瞻性随机对照证据。
  • 研究间可能存在异质性,原文未报告具体异质性检验数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neoadjuvant concurrent chemoradiation therapy (nCRT) plus surgery has been a standard treatment for locoregionally advanced esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ), but the optimal preoperative radiation dose is still unclear. We performed this systematic review to explore the treatment efficacy and toxicity of different radiation dose levels and find an optimal dose-fractionation strategy in EC/GEJ patients receiving nCRT. METHODS AND MATERIALS: Embase and Ovid Medline were searched for articles involving cases of operable squamous and adenocarcinoma of the esophagus and GEJ in which patients received nCRT up to a dose of 50.4 Gy in 28 fractions that were published until July 2019, when the search was performed. Physical dose distributions were converted to biologically equivalent doses (BEDs), which were described in units of gray (alpha/beta). Pooled rates of overall survival (OS), progression-free survival (PFS), failure patterns, and toxicities were compared between lower-dose radiation therapy (LDRT; BED ≤48.85 Gy10) and higher-dose radiation therapy (HDRT; BED >48.85 Gy10) for patients treated with nCRT. RESULTS: A total of 110 studies with 7577 EC/GEJ patients receiving nCRT were included in this pooled analysis. Both the PFS and OS rates of patients receiving LDRT were significantly higher than those of patients receiving HDRT. Patients receiving LDRT had improved safety regarding treatment-related adverse events and lower distant failure rates than patients receiving HDRT. Utilization of modern radiation therapy (RT) techniques, including 3-dimensional conformal RT and intensity modulated RT, was associated with improved oncologic outcomes compared with 2-dimensional methods. Subgroup analysis showed that EC/GEJ patients receiving conventionally fractionated radiation to a dose of 40.0 to 41.4 Gy in 20-23 fractions showed improved OS compared with those receiving radiation above this dose. CONCLUSIONS: Based on the limited data, nCRT using BED ≤48.85 Gy10 was suitable for locoregionally advanced, resectable EC/GEJ. A total dose of 40.0 to 41.4 Gy in 20 to 23 fractions using modern RT techniques might provide the optimal therapeutic ratio.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li Y, Liu H, Sun C, et al. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review. Int J Radiat Oncol Biol Phys. 2021. PMID: 33964352. doi:10.1016/j.ijrobp.2021.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。